Effect of Lenvatinib Combined with TACE on Tumor Markers,Apoptotic Molecules and Serum ST6GAL1,ANG-2 and HGF in Patients with Unresectable Hepatocellular Carcinoma
Objective:To investigate the effects of lenvatinib combined with transcatheter arterial chemoembolization(TACE)on tumor markers,apoptotic molecules,serum sialic acid transferase 1(ST6Gal1),angiopoietin-2(ANG-2)and hepatocyte growth factor(HGF)in patients with unresectable hepatocellular carcinoma.Methods:114 patients with unresectable hepatocellular carcinoma who were admitted to Sichuan Mianyang 404 Hospital from March 2020 to December 2022 were divided into control group(n=57,TACE treatment)and study group(n=57,lenvatinib combine with TACE treatment)by random number table method.The efficacy,tumor mark-ers[alpha-fetoprotein(AFP),carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA)],serum apoptotic molecules[B-cell lymphoma-2-associated X protein(Bax),B-cell lymphoma-2 gene(Bcl-2),survivin(Survivin),cysteine aspartic protease-4(Caspase-4)]and serum ST6Gall,ANG-2,HGF levels were compared between two groups,and the incidence of adverse reactions during treatment was observed.Results:Compared with control group,the total clinical effective rate in study group was higher(P＜0.05).Compared with control group,the levels of AFP,CA1 99 and CEA in study group were lower after treatment(P＜0.05).Compared with control group,the levels of Bcl-2 and Survivin in study group were lower after treatment,and the levels of Bax and Caspase-4 were higher(P＜0.05).Com-pared with control group,the levels of ST6Gall,ANG-2 and HGF in study group were lower after treatment(P＜0.05).There was no dif-ference in the total incidence of adverse reactions between two groups(P＞0.05).Conclusion:Lenvatinib combined with TACE for patients with unresectable hepatocellular carcinoma,which can improve the clinical treatment effect,regulate the levels of tumor markers,apoptotic molecules and serum ST6Gall,ANG-2 and HGF,with good safety.
NETL
NSTL
万方数据
